research Attitudes and practices of dermatologists and primary care physicians who treat patients for MPHL: results of a survey
Dermatologists are more comfortable and proactive in treating male pattern hair loss than primary care physicians.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research Androgenetic alopecia: Does its presence change our perceptions?
Hair loss seen as natural; short haircuts help cope.
research A Method for Evaluating and Treating the Temporal Peak Region in Patients with Male Pattern Baldness
The method improves natural appearance in hair restoration by properly evaluating and treating the temporal peak region.
research Scalp cooling in the prevention of anthracycline-induced alopecia
Scalp cooling prevented hair loss in half of the patients, despite significant side effects.
research A practical approach to feline symmetrical alopecia
The conclusion is to thoroughly test for causes of cat hair loss and treat accordingly, considering medication only after serious conditions are ruled out.
research TMT-Based Quantitative Proteomic Analysis Reveals the Effect of Bone Marrow Derived Mesenchymal Stem Cell on Hair Follicle Regeneration
Bone marrow stem cells and their medium help hair regrowth.
research Retrospective Study about the Causes and the Effects of Korean Medicine Treatment on Alopecia - Focused on Acquired Febrile Alopecia -
Korean medicine effectively treats febrile alopecia, shifting focus from genetic to febrile causes.
research Long-Term Evaluation of Endoscopic and Pretrichial Open Forehead Lifts: A Morphometric Analysis
Both endoscopic and pretrichial open forehead lifts effectively elevate eyebrows long-term with high patient satisfaction.
research Self-Assessments of Standardized Scalp Massages for Androgenic Alopecia: Survey Results
Scalp massages may help stabilize or regrow hair in people suffering from hair loss, regardless of age, gender, or use of other treatments.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.